Autonomic function and prognosis

Article Type
Changed
Tue, 10/02/2018 - 12:14
Display Headline
Autonomic function and prognosis

First-year medical students are well aware that the autonomic nervous system regulates heart rate and blood pressure along with respiratory and digestive functions. The past 10 to 20 years have seen increased appreciation of the medical relevance of the the autonomic nervous system beyond first-year physiology examinations; even mild disturbances of autonomic nervous system function predict materially worse prognosis.1–3 Researchers have focused on the use of readily available measures, such as heart rate,4 heart rate variability,5 and heart rate recovery,6 to link autonomic nervous system dysfunction with mortality and morbidity.1 In addition, epidemiologists have exploited these tools to identify correlates of autonomic nervous system dysfunction at patient and environmental levels.7 Although it is not yet known how best to incorporate autonomic nervous system measures into routine clinical care, there is increasing excitement about the insights that this work has revealed.

MEASURES OF AUTONOMIC NERVOUS SYSTEM FUNCTION

Although many measures of autonomic nervous system function have been described, three relatively straightforward approaches are based on heart rate.1

Resting heart rate is the simplest to obtain, as it does not require any special technology. People with high levels of parasympathetic nervous system tone have lower resting heart rates, as is typically seen in world-class athletes. Conversely, conditions characterized by increased levels of sympathetic tone manifest as sinus tachycardia; classic examples include congestive heart failure, anemia, and hypovolemia.

Reprinted, with permission, from Annals of Internal Medicine (van Ravenswaaij-Arts et al. Heart rate variability. Ann Intern Med 1993; 118:436–447).
Figure 1. Example of time-domain measures of heart rate variability (STV = short-term variability; LTV = long-term variability). The top plot shows heart rate as a function of time. In the bottom plot, Fourier transform yields power values of very-low-frequency (VLF), low-frequency (LF), and high-frequency (HF) domains. The high-frequency domain is thought to reflect parasympathetic tone, where-as the very-low-frequency and low-frequency domains are thought to reflect a mixture of parasympathetic and sympathetic tone.
Heart rate variability. Even before the advent of the electrocardiogram, it was known that heart rate normally varies with respiration.8 Physiologic sinus arrhythmia can be easily demonstrated by plotting heart rate over time in resting supine subjects, typically yielding a tracing characterized by high-frequency, low-amplitude waves. When a normal subject assumes an upright position, the resting heart rate increases and there is an increased absolute amount of variability, but the frequency of the variability wave decreases. Using Fourier transform techniques, one can translate the amplitude and frequency of the waves shown in the top plot of Figure 1 into power domain functions, as shown in the bottom plot of Figure 1.8 Heart rate variability functions can be divided into high-frequency, low-frequency, and very-low-frequency domains.8,9 The high-frequency peak, which is reflective of the very fine variability seen with respiration at rest, is thought to reflect parasympathetic nervous system tone. The low-frequency and very-low-frequency peaks are thought to reflect mixed effects of parasympathetic tone and sympathetic tone.

Heart rate recovery. Heart rate variability measures require continuous Holter monitoring as well as sophisticated software. The numerous types of heart rate variability measures are not intuitive for most clinicians. Exercise heart rate recovery is an arguably more straightforward method of assessing parasympathetic tone.1 During a graded exercise test, heart rate increases as a result of withdrawal of parasympathetic tone and increased sympathetic tone. During the first 30 seconds after exercise, heart rate decreases quickly, mainly because of rapid reactivation of the parasympathetic nervous system.10

Figure 2. Demonstration of the association between parasympathetic tone and heart rate recovery. (A) Absolute heart rates (after logarithmic transformation) are shown during the first 2 minutes after exercise in three groups of subjects. Among athletes and normal subjects, there is a biexponential relationship. (B) Postexercise absolute heart rates are shown again, this time after administration of atropine, in which case the initial steep slope disappears.  Figure is based on data from Imai et al.10
The association between early heart rate recovery and parasympathetic nervous system function was demonstrated elegantly by Imai and colleagues in a study of three groups of subjects—athletes, normal subjects, and patients with heart failure.10 Among athletes and normal subjects there was a biexponential pattern of heart rate during early recovery, with a steep log-linear decrease during the first 30 seconds followed by a more shallow decline (Figure 2A). When the same subjects were given atropine and exercise testing was repeated, the initial steep decrease in heart rate observed among athletes and normal subjects disappeared (Figure 2B). The authors concluded that early heart rate recovery is primarily a manifestation of parasympathetic reactivation.

AUTONOMIC NERVOUS SYSTEM FUNCTION AND MORTALITY

Resting heart rate

There is a remarkably strong association between heart rate and survival, an association that transcends species.4 Small mammals that have rapid heart rates have short life expectancies. Larger mammals that have slower heart rates have correspondingly higher life expectancies. Among nearly all mammals, life expectancy is close to 1 billion heartbeats.

Investigators have been able to increase survival in animal models by deliberate slowing of heart rate. An experiment performed in mice more than 30 years ago showed that life expectancy increases with low-dose digoxin, a parasympathomimetic agent.11 More recently, a mouse model has been used to show that ivabradine, a sinus node ion channel blocking agent that specifically reduces heart rate without affecting vascular tone, inhibits development of atherosclerosis in genetically susceptible knockout mice.12

There is an extensive epidemiological literature linking heart rate to mortality in large human populations. 4,13 As heart rate increases to 75 to 80 beats per minute, there are marked increases in total mortality and mortality due to coronary heart disease. As is well known, administration of beta-blockers reduces mortality in survivors of myocardial infarction. What is particularly remarkable is that the magnitude of reduction in mortality with beta-blocker therapy is directly proportional to the magnitude of heart rate decrease.14 In a recent analysis of hypertensive patients enrolled in a large-scale randomized trial, a strong association was noted between mortality and increasing heart rate at the time of randomization as well as after treatment with either verapamil or a beta-blocker.15

Heart rate variability

Figure 3. Association between measures of heart rate variability and cardiac events in the Framingham Heart Study. Each measure is divided into tertiles from lowest to highest (SDNN = standard deviation of R-R intervals of normal beats; LF = low-frequency power; HF = high-frequency power; LF/HF = ratio of LF power to HF power). Figure is based on data from Tsuji et al.16
Just as with resting heart rate, there is a robust literature linking decreased heart rate variability to cardiac events and mortality. Among healthy elderly subjects enrolled in the Framingham Heart Study, decreased heart rate variability was associated with a substantially increased likelihood of major cardiac events (Figure 3).16 The Framingham investigators measured the standard deviation of R-R intervals that do not include ventricular ectopic beats (SDNN) as well as time-domain measures. Lower values of the ratio of low-frequency power to high-frequency power, which would correspond to lower levels of parasympathetic tone, were also associated with increased mortality. Similarly, among survivors of myocardial infarction, especially those with low ejection fractions, decreased heart rate variability predicted substantially higher mortality rates.5,17,18

 

 

Heart rate recovery

In 1999, Cole and colleagues reported on the association between heart rate recovery during the first minute after exercise and all-cause mortality in approximately 2,400 patients who were candidates for first-time coronary angiography.6 An abnormal heart rate recovery was defined as a reduction from the peak heart rate of 12 beats per minute or less, which corresponded to the lowest quartile. Thus, a patient achieving a peak heart rate of 160 beats per minute would be considered to have an abnormal heart rate recovery if 1 minute later the heart rate was 148 beats per minute or higher. Patients who had an abnormal heart rate recovery had a nearly fourfold increased risk of all-cause death; even after adjusting for numerous confounders, including exercise capacity, there was still a twofold independent increased risk of death. This initial observation has since been confirmed in other cohorts.19,20 The link between heart rate recovery, mortality, and cardiovascular prognosis appears to be independent of symptom status,21 type of recovery protocol,22 left ventricular ejection fraction,22 and angiographic severity of coronary artery disease.23

The mechanism by which an abnormal heart rate recovery predicts increased mortality is unclear. Given that heart rate recovery is thought to reflect parasympathetic nervous system function, and given that increased parasympathetic tone is believed to have antiarrhythmic effects, one might hypothesize that lower heart rate recovery would predict sudden cardiac death. In 2005, investigators from the Paris Civil Service Study reported on the association of exercise heart rate recovery and type of mortality; low heart rate recovery was strongly predictive of sudden cardiac death but not of non-sudden cardiac myocardial infarction death.20 A separate study from the Cleveland Clinic showed that among more than 29,000 patients, frequent ventricular ectopy during early recovery was strongly predictive of death, whereas frequent ventricular ectopy during exercise was not.24 These two studies together suggest that the link between heart rate recovery and mortality may be a reflection of the antiarrhythmic properties of the parasympathetic nervous system.

It is well known that there is an exceptionally powerful link between functional capacity and cardiovascular risk.25,26 People who are in excellent physical shape have high levels of parasympathetic tone. Among patients with suspected coronary artery disease, there is a strong dose-response relationship between heart rate recovery and physical fitness.6 While the link between functional capacity and prognosis is complex, it is conceivable that parasympathetic protection against arrhythmias and shear-induced plaque rupture may play a role.

Figure 4. User interface of an externally validated mortality prediction model for primary prevention patients with normal electrocardiograms undergoing exercise testing.27 This prediction model includes easily obtained cardiovascular risk factors as well as measures of autonomic function.
Both heart rate recovery and functional capacity are easy to measure using standard exercise test equipment. Recently, investigators from the Cleveland Clinic and Kaiser Permanente derived and externally validated a simple multivariable instrument by which all-cause mortality can be predicted in subjects with a normal electrocardiogram and no history of coronary disease.27 This instrument includes measures of functional capacity, heart rate recovery, and frequent ventricular ectopy during recovery. An example of the user interface is shown in Figure 4.

DETERMINANTS OF AUTONOMIC NERVOUS SYSTEM FUNCTION

There is an extensive literature documenting a number of determinants of autonomic tone.3,7 On a patient level, decreased levels of parasympathetic tone or increased levels of sympathetic tone have been linked to obesity, insulin resistance, diabetes, hypertension, hypercholesterolemia, depression, anxiety, heart failure, and peripheral vascular disease.3

Copyright © 2002 American Diabetes Association. From Diabetes®, Vol. 51, 2002; 803–807. Adapted with permission from The American Diabetes Association.
Figure 5. Association of fasting plasma glucose with abnormal heart rate recovery among healthy subjects enrolled in the Lipid Research Clinics observational cohort study.
The association between diabetes and autonomic nervous system dysfunction is well known to clinicians caring for patients with clinically manifest autonomic neuropathy. What is less appreciated is that even minor degrees of glucose intolerance are associated with abnormalities of autonomic balance. For example, among patients enrolled in a population-based cohort, the likelihood of an abnormal heart rate recovery increased in a steady fashion as fasting plasma glucose increased from 70 to 80 to 90 mg/dL and above (Figure 5).28 Even at levels of plasma glucose that would be considered normal, the likelihood of an abnormal heart rate recovery increased as plasma glucose increased.28

Perturbations of autonomic nervous system function have also been associated with environmental exposures. People who have lower levels of education,29 live in neighborhoods characterized by lower socio-economic status,30 or are exposed to small-particulate air pollution31 have been shown to manifest abnormal heart rate recovery or decreased heart rate variability.

CONCLUSIONS

Autonomic nervous system function can be measured in the clinic by recording resting heart rate, heart rate variability, or exercise heart rate recovery.1 All three of these measures are strong predictors of cardiovascular risk and all-cause mortality in both primary and secondary prevention settings. A number of determinants of autonomic nervous system function have been identified, including patient-level factors like obesity, diabetes, and heart failure as well as environmental correlates like smoking, social stress, and air pollution. It is not yet known, however, how best to take advantage of the associations between abnormal autonomic nervous system function and poor prognosis to improve patient outcomes. Future research will be needed to identify strategies of favorably modulating autonomic function that improve outcomes in the clinic and among large populations.

References
  1. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol 2008; 51:17251733.
  2. Katz A, Liberty IF, Porath A, Ovsyshcher I, Prystowsky EN. A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. Am Heart J 1999; 138(1 Pt 1):3238.
  3. Curtis BM, O’Keefe JH. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc 2002; 77:4554.
  4. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997; 30:11041106.
  5. Huikuri HV, Makikallio T, Airaksinen KE, Mitrani R, Castellanos A, Myerburg RJ. Measurement of heart rate variability: a clinical tool or a research toy? J Am Coll Cardiol 1999; 34:18781883.
  6. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999; 341:13511357.
  7. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 2007; 74:224242.
  8. van Ravenswaaij-Arts CM, Kollee LA, Hopman JC, Stoelinga GB, van Geijn HP. Heart rate variability. Ann Intern Med 1993; 118:436447.
  9. Pumprla J, Howorka K, Groves D, Chester M, Nolan J. Functional assessment of heart rate variability: physiological basis and practical applications. Int J Cardiol 2002; 84:114.
  10. Imai K, Sato H, Hori M, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol 1994; 24:15291535.
  11. Coburn AF, Grey RM, Rivera SM. Observations on the relation of heart rate, life span, weight and mineralization in the digoxintreated A-J mouse. Johns Hopkins Med J 1971; 128:169193.
  12. Custodis F, Baumhakel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008; 117:23772387.
  13. Wilhelmsen L, Berglund G, Elmfeldt D, et al. The multifactor primary prevention trial in GÖteborg, Sweden. Eur Heart J 1986; 7:279288.
  14. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 2007; 96:585592.
  15. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29:13271334.
  16. Tsuji H, Larson MG, Venditti FJ, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996; 94:28502855.
  17. Makikallio TH, Hoiber S, Kober L, et al. Fractal analysis of heart rate dynamics as a predictor of mortality in patients with depressed left ventricular function after acute myocardial infarction. TRACE Investigators. TRAndolapril Cardiac Evaluation. Am J Cardiol 1999; 83:836839.
  18. La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351:478484.
  19. Shetler K, Marcus R, Froelicher VF, et al. Heart rate recovery: validation and methodologic issues. J Am Coll Cardiol 2001; 38:19801987.
  20. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352:19511958.
  21. Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med 2000; 132:552555.
  22. Watanabe J, Thamilarasan M, Blackstone EH, Thomas JD, Lauer MS. Heart rate recovery immediately after treadmill exercise and left ventricular systolic dysfunction as predictors of mortality: the case of stress echocardiography. Circulation 2001; 104:19111916.
  23. Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am Coll Cardiol 2003; 42:831838.
  24. Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 2003; 348:781790.
  25. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793801.
  26. Gulati M, Black HR, Shaw LJ, et al. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med 2005; 353:468475.
  27. Lauer MS, Pothier CE, Magid DJ, Smith SS, Kattan MW. An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med 2007; 147:821828.
  28. Panzer C, Lauer MS, Brieke A, Blackstone E, Hoogwerf B. Association of fasting plasma glucose with heart rate recovery in healthy adults: a population-based study. Diabetes 2002; 51:803807.
  29. Shishehbor MH, Baker DW, Blackstone EH, Lauer MS. Association of educational status with heart rate recovery: a population-based propensity analysis. Am J Med 2002; 113:643649.
  30. Shishehbor MH, Litaker D, Pothier CE, Lauer MS. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA 2006; 295:784792.
  31. Magari SR, Hauser R, Schwartz J, Williams PL, Smith TJ, Christiani DC. Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation 2001; 104:986991.
Article PDF
Author and Disclosure Information

Michael S. Lauer, MD
Director, Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD

Correspondence: Michael S. Lauer, MD, Director, Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Rockledge Center II, Room 10021, Bethesda, MD 20892; lauerm@nhlbi.nih.gov

Dr. Lauer reported that he has no fianancial interests or relationships that pose a potential conflict of interest with this article.

Publications
Page Number
S18-S22
Author and Disclosure Information

Michael S. Lauer, MD
Director, Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD

Correspondence: Michael S. Lauer, MD, Director, Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Rockledge Center II, Room 10021, Bethesda, MD 20892; lauerm@nhlbi.nih.gov

Dr. Lauer reported that he has no fianancial interests or relationships that pose a potential conflict of interest with this article.

Author and Disclosure Information

Michael S. Lauer, MD
Director, Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD

Correspondence: Michael S. Lauer, MD, Director, Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Rockledge Center II, Room 10021, Bethesda, MD 20892; lauerm@nhlbi.nih.gov

Dr. Lauer reported that he has no fianancial interests or relationships that pose a potential conflict of interest with this article.

Article PDF
Article PDF

First-year medical students are well aware that the autonomic nervous system regulates heart rate and blood pressure along with respiratory and digestive functions. The past 10 to 20 years have seen increased appreciation of the medical relevance of the the autonomic nervous system beyond first-year physiology examinations; even mild disturbances of autonomic nervous system function predict materially worse prognosis.1–3 Researchers have focused on the use of readily available measures, such as heart rate,4 heart rate variability,5 and heart rate recovery,6 to link autonomic nervous system dysfunction with mortality and morbidity.1 In addition, epidemiologists have exploited these tools to identify correlates of autonomic nervous system dysfunction at patient and environmental levels.7 Although it is not yet known how best to incorporate autonomic nervous system measures into routine clinical care, there is increasing excitement about the insights that this work has revealed.

MEASURES OF AUTONOMIC NERVOUS SYSTEM FUNCTION

Although many measures of autonomic nervous system function have been described, three relatively straightforward approaches are based on heart rate.1

Resting heart rate is the simplest to obtain, as it does not require any special technology. People with high levels of parasympathetic nervous system tone have lower resting heart rates, as is typically seen in world-class athletes. Conversely, conditions characterized by increased levels of sympathetic tone manifest as sinus tachycardia; classic examples include congestive heart failure, anemia, and hypovolemia.

Reprinted, with permission, from Annals of Internal Medicine (van Ravenswaaij-Arts et al. Heart rate variability. Ann Intern Med 1993; 118:436–447).
Figure 1. Example of time-domain measures of heart rate variability (STV = short-term variability; LTV = long-term variability). The top plot shows heart rate as a function of time. In the bottom plot, Fourier transform yields power values of very-low-frequency (VLF), low-frequency (LF), and high-frequency (HF) domains. The high-frequency domain is thought to reflect parasympathetic tone, where-as the very-low-frequency and low-frequency domains are thought to reflect a mixture of parasympathetic and sympathetic tone.
Heart rate variability. Even before the advent of the electrocardiogram, it was known that heart rate normally varies with respiration.8 Physiologic sinus arrhythmia can be easily demonstrated by plotting heart rate over time in resting supine subjects, typically yielding a tracing characterized by high-frequency, low-amplitude waves. When a normal subject assumes an upright position, the resting heart rate increases and there is an increased absolute amount of variability, but the frequency of the variability wave decreases. Using Fourier transform techniques, one can translate the amplitude and frequency of the waves shown in the top plot of Figure 1 into power domain functions, as shown in the bottom plot of Figure 1.8 Heart rate variability functions can be divided into high-frequency, low-frequency, and very-low-frequency domains.8,9 The high-frequency peak, which is reflective of the very fine variability seen with respiration at rest, is thought to reflect parasympathetic nervous system tone. The low-frequency and very-low-frequency peaks are thought to reflect mixed effects of parasympathetic tone and sympathetic tone.

Heart rate recovery. Heart rate variability measures require continuous Holter monitoring as well as sophisticated software. The numerous types of heart rate variability measures are not intuitive for most clinicians. Exercise heart rate recovery is an arguably more straightforward method of assessing parasympathetic tone.1 During a graded exercise test, heart rate increases as a result of withdrawal of parasympathetic tone and increased sympathetic tone. During the first 30 seconds after exercise, heart rate decreases quickly, mainly because of rapid reactivation of the parasympathetic nervous system.10

Figure 2. Demonstration of the association between parasympathetic tone and heart rate recovery. (A) Absolute heart rates (after logarithmic transformation) are shown during the first 2 minutes after exercise in three groups of subjects. Among athletes and normal subjects, there is a biexponential relationship. (B) Postexercise absolute heart rates are shown again, this time after administration of atropine, in which case the initial steep slope disappears.  Figure is based on data from Imai et al.10
The association between early heart rate recovery and parasympathetic nervous system function was demonstrated elegantly by Imai and colleagues in a study of three groups of subjects—athletes, normal subjects, and patients with heart failure.10 Among athletes and normal subjects there was a biexponential pattern of heart rate during early recovery, with a steep log-linear decrease during the first 30 seconds followed by a more shallow decline (Figure 2A). When the same subjects were given atropine and exercise testing was repeated, the initial steep decrease in heart rate observed among athletes and normal subjects disappeared (Figure 2B). The authors concluded that early heart rate recovery is primarily a manifestation of parasympathetic reactivation.

AUTONOMIC NERVOUS SYSTEM FUNCTION AND MORTALITY

Resting heart rate

There is a remarkably strong association between heart rate and survival, an association that transcends species.4 Small mammals that have rapid heart rates have short life expectancies. Larger mammals that have slower heart rates have correspondingly higher life expectancies. Among nearly all mammals, life expectancy is close to 1 billion heartbeats.

Investigators have been able to increase survival in animal models by deliberate slowing of heart rate. An experiment performed in mice more than 30 years ago showed that life expectancy increases with low-dose digoxin, a parasympathomimetic agent.11 More recently, a mouse model has been used to show that ivabradine, a sinus node ion channel blocking agent that specifically reduces heart rate without affecting vascular tone, inhibits development of atherosclerosis in genetically susceptible knockout mice.12

There is an extensive epidemiological literature linking heart rate to mortality in large human populations. 4,13 As heart rate increases to 75 to 80 beats per minute, there are marked increases in total mortality and mortality due to coronary heart disease. As is well known, administration of beta-blockers reduces mortality in survivors of myocardial infarction. What is particularly remarkable is that the magnitude of reduction in mortality with beta-blocker therapy is directly proportional to the magnitude of heart rate decrease.14 In a recent analysis of hypertensive patients enrolled in a large-scale randomized trial, a strong association was noted between mortality and increasing heart rate at the time of randomization as well as after treatment with either verapamil or a beta-blocker.15

Heart rate variability

Figure 3. Association between measures of heart rate variability and cardiac events in the Framingham Heart Study. Each measure is divided into tertiles from lowest to highest (SDNN = standard deviation of R-R intervals of normal beats; LF = low-frequency power; HF = high-frequency power; LF/HF = ratio of LF power to HF power). Figure is based on data from Tsuji et al.16
Just as with resting heart rate, there is a robust literature linking decreased heart rate variability to cardiac events and mortality. Among healthy elderly subjects enrolled in the Framingham Heart Study, decreased heart rate variability was associated with a substantially increased likelihood of major cardiac events (Figure 3).16 The Framingham investigators measured the standard deviation of R-R intervals that do not include ventricular ectopic beats (SDNN) as well as time-domain measures. Lower values of the ratio of low-frequency power to high-frequency power, which would correspond to lower levels of parasympathetic tone, were also associated with increased mortality. Similarly, among survivors of myocardial infarction, especially those with low ejection fractions, decreased heart rate variability predicted substantially higher mortality rates.5,17,18

 

 

Heart rate recovery

In 1999, Cole and colleagues reported on the association between heart rate recovery during the first minute after exercise and all-cause mortality in approximately 2,400 patients who were candidates for first-time coronary angiography.6 An abnormal heart rate recovery was defined as a reduction from the peak heart rate of 12 beats per minute or less, which corresponded to the lowest quartile. Thus, a patient achieving a peak heart rate of 160 beats per minute would be considered to have an abnormal heart rate recovery if 1 minute later the heart rate was 148 beats per minute or higher. Patients who had an abnormal heart rate recovery had a nearly fourfold increased risk of all-cause death; even after adjusting for numerous confounders, including exercise capacity, there was still a twofold independent increased risk of death. This initial observation has since been confirmed in other cohorts.19,20 The link between heart rate recovery, mortality, and cardiovascular prognosis appears to be independent of symptom status,21 type of recovery protocol,22 left ventricular ejection fraction,22 and angiographic severity of coronary artery disease.23

The mechanism by which an abnormal heart rate recovery predicts increased mortality is unclear. Given that heart rate recovery is thought to reflect parasympathetic nervous system function, and given that increased parasympathetic tone is believed to have antiarrhythmic effects, one might hypothesize that lower heart rate recovery would predict sudden cardiac death. In 2005, investigators from the Paris Civil Service Study reported on the association of exercise heart rate recovery and type of mortality; low heart rate recovery was strongly predictive of sudden cardiac death but not of non-sudden cardiac myocardial infarction death.20 A separate study from the Cleveland Clinic showed that among more than 29,000 patients, frequent ventricular ectopy during early recovery was strongly predictive of death, whereas frequent ventricular ectopy during exercise was not.24 These two studies together suggest that the link between heart rate recovery and mortality may be a reflection of the antiarrhythmic properties of the parasympathetic nervous system.

It is well known that there is an exceptionally powerful link between functional capacity and cardiovascular risk.25,26 People who are in excellent physical shape have high levels of parasympathetic tone. Among patients with suspected coronary artery disease, there is a strong dose-response relationship between heart rate recovery and physical fitness.6 While the link between functional capacity and prognosis is complex, it is conceivable that parasympathetic protection against arrhythmias and shear-induced plaque rupture may play a role.

Figure 4. User interface of an externally validated mortality prediction model for primary prevention patients with normal electrocardiograms undergoing exercise testing.27 This prediction model includes easily obtained cardiovascular risk factors as well as measures of autonomic function.
Both heart rate recovery and functional capacity are easy to measure using standard exercise test equipment. Recently, investigators from the Cleveland Clinic and Kaiser Permanente derived and externally validated a simple multivariable instrument by which all-cause mortality can be predicted in subjects with a normal electrocardiogram and no history of coronary disease.27 This instrument includes measures of functional capacity, heart rate recovery, and frequent ventricular ectopy during recovery. An example of the user interface is shown in Figure 4.

DETERMINANTS OF AUTONOMIC NERVOUS SYSTEM FUNCTION

There is an extensive literature documenting a number of determinants of autonomic tone.3,7 On a patient level, decreased levels of parasympathetic tone or increased levels of sympathetic tone have been linked to obesity, insulin resistance, diabetes, hypertension, hypercholesterolemia, depression, anxiety, heart failure, and peripheral vascular disease.3

Copyright © 2002 American Diabetes Association. From Diabetes®, Vol. 51, 2002; 803–807. Adapted with permission from The American Diabetes Association.
Figure 5. Association of fasting plasma glucose with abnormal heart rate recovery among healthy subjects enrolled in the Lipid Research Clinics observational cohort study.
The association between diabetes and autonomic nervous system dysfunction is well known to clinicians caring for patients with clinically manifest autonomic neuropathy. What is less appreciated is that even minor degrees of glucose intolerance are associated with abnormalities of autonomic balance. For example, among patients enrolled in a population-based cohort, the likelihood of an abnormal heart rate recovery increased in a steady fashion as fasting plasma glucose increased from 70 to 80 to 90 mg/dL and above (Figure 5).28 Even at levels of plasma glucose that would be considered normal, the likelihood of an abnormal heart rate recovery increased as plasma glucose increased.28

Perturbations of autonomic nervous system function have also been associated with environmental exposures. People who have lower levels of education,29 live in neighborhoods characterized by lower socio-economic status,30 or are exposed to small-particulate air pollution31 have been shown to manifest abnormal heart rate recovery or decreased heart rate variability.

CONCLUSIONS

Autonomic nervous system function can be measured in the clinic by recording resting heart rate, heart rate variability, or exercise heart rate recovery.1 All three of these measures are strong predictors of cardiovascular risk and all-cause mortality in both primary and secondary prevention settings. A number of determinants of autonomic nervous system function have been identified, including patient-level factors like obesity, diabetes, and heart failure as well as environmental correlates like smoking, social stress, and air pollution. It is not yet known, however, how best to take advantage of the associations between abnormal autonomic nervous system function and poor prognosis to improve patient outcomes. Future research will be needed to identify strategies of favorably modulating autonomic function that improve outcomes in the clinic and among large populations.

First-year medical students are well aware that the autonomic nervous system regulates heart rate and blood pressure along with respiratory and digestive functions. The past 10 to 20 years have seen increased appreciation of the medical relevance of the the autonomic nervous system beyond first-year physiology examinations; even mild disturbances of autonomic nervous system function predict materially worse prognosis.1–3 Researchers have focused on the use of readily available measures, such as heart rate,4 heart rate variability,5 and heart rate recovery,6 to link autonomic nervous system dysfunction with mortality and morbidity.1 In addition, epidemiologists have exploited these tools to identify correlates of autonomic nervous system dysfunction at patient and environmental levels.7 Although it is not yet known how best to incorporate autonomic nervous system measures into routine clinical care, there is increasing excitement about the insights that this work has revealed.

MEASURES OF AUTONOMIC NERVOUS SYSTEM FUNCTION

Although many measures of autonomic nervous system function have been described, three relatively straightforward approaches are based on heart rate.1

Resting heart rate is the simplest to obtain, as it does not require any special technology. People with high levels of parasympathetic nervous system tone have lower resting heart rates, as is typically seen in world-class athletes. Conversely, conditions characterized by increased levels of sympathetic tone manifest as sinus tachycardia; classic examples include congestive heart failure, anemia, and hypovolemia.

Reprinted, with permission, from Annals of Internal Medicine (van Ravenswaaij-Arts et al. Heart rate variability. Ann Intern Med 1993; 118:436–447).
Figure 1. Example of time-domain measures of heart rate variability (STV = short-term variability; LTV = long-term variability). The top plot shows heart rate as a function of time. In the bottom plot, Fourier transform yields power values of very-low-frequency (VLF), low-frequency (LF), and high-frequency (HF) domains. The high-frequency domain is thought to reflect parasympathetic tone, where-as the very-low-frequency and low-frequency domains are thought to reflect a mixture of parasympathetic and sympathetic tone.
Heart rate variability. Even before the advent of the electrocardiogram, it was known that heart rate normally varies with respiration.8 Physiologic sinus arrhythmia can be easily demonstrated by plotting heart rate over time in resting supine subjects, typically yielding a tracing characterized by high-frequency, low-amplitude waves. When a normal subject assumes an upright position, the resting heart rate increases and there is an increased absolute amount of variability, but the frequency of the variability wave decreases. Using Fourier transform techniques, one can translate the amplitude and frequency of the waves shown in the top plot of Figure 1 into power domain functions, as shown in the bottom plot of Figure 1.8 Heart rate variability functions can be divided into high-frequency, low-frequency, and very-low-frequency domains.8,9 The high-frequency peak, which is reflective of the very fine variability seen with respiration at rest, is thought to reflect parasympathetic nervous system tone. The low-frequency and very-low-frequency peaks are thought to reflect mixed effects of parasympathetic tone and sympathetic tone.

Heart rate recovery. Heart rate variability measures require continuous Holter monitoring as well as sophisticated software. The numerous types of heart rate variability measures are not intuitive for most clinicians. Exercise heart rate recovery is an arguably more straightforward method of assessing parasympathetic tone.1 During a graded exercise test, heart rate increases as a result of withdrawal of parasympathetic tone and increased sympathetic tone. During the first 30 seconds after exercise, heart rate decreases quickly, mainly because of rapid reactivation of the parasympathetic nervous system.10

Figure 2. Demonstration of the association between parasympathetic tone and heart rate recovery. (A) Absolute heart rates (after logarithmic transformation) are shown during the first 2 minutes after exercise in three groups of subjects. Among athletes and normal subjects, there is a biexponential relationship. (B) Postexercise absolute heart rates are shown again, this time after administration of atropine, in which case the initial steep slope disappears.  Figure is based on data from Imai et al.10
The association between early heart rate recovery and parasympathetic nervous system function was demonstrated elegantly by Imai and colleagues in a study of three groups of subjects—athletes, normal subjects, and patients with heart failure.10 Among athletes and normal subjects there was a biexponential pattern of heart rate during early recovery, with a steep log-linear decrease during the first 30 seconds followed by a more shallow decline (Figure 2A). When the same subjects were given atropine and exercise testing was repeated, the initial steep decrease in heart rate observed among athletes and normal subjects disappeared (Figure 2B). The authors concluded that early heart rate recovery is primarily a manifestation of parasympathetic reactivation.

AUTONOMIC NERVOUS SYSTEM FUNCTION AND MORTALITY

Resting heart rate

There is a remarkably strong association between heart rate and survival, an association that transcends species.4 Small mammals that have rapid heart rates have short life expectancies. Larger mammals that have slower heart rates have correspondingly higher life expectancies. Among nearly all mammals, life expectancy is close to 1 billion heartbeats.

Investigators have been able to increase survival in animal models by deliberate slowing of heart rate. An experiment performed in mice more than 30 years ago showed that life expectancy increases with low-dose digoxin, a parasympathomimetic agent.11 More recently, a mouse model has been used to show that ivabradine, a sinus node ion channel blocking agent that specifically reduces heart rate without affecting vascular tone, inhibits development of atherosclerosis in genetically susceptible knockout mice.12

There is an extensive epidemiological literature linking heart rate to mortality in large human populations. 4,13 As heart rate increases to 75 to 80 beats per minute, there are marked increases in total mortality and mortality due to coronary heart disease. As is well known, administration of beta-blockers reduces mortality in survivors of myocardial infarction. What is particularly remarkable is that the magnitude of reduction in mortality with beta-blocker therapy is directly proportional to the magnitude of heart rate decrease.14 In a recent analysis of hypertensive patients enrolled in a large-scale randomized trial, a strong association was noted between mortality and increasing heart rate at the time of randomization as well as after treatment with either verapamil or a beta-blocker.15

Heart rate variability

Figure 3. Association between measures of heart rate variability and cardiac events in the Framingham Heart Study. Each measure is divided into tertiles from lowest to highest (SDNN = standard deviation of R-R intervals of normal beats; LF = low-frequency power; HF = high-frequency power; LF/HF = ratio of LF power to HF power). Figure is based on data from Tsuji et al.16
Just as with resting heart rate, there is a robust literature linking decreased heart rate variability to cardiac events and mortality. Among healthy elderly subjects enrolled in the Framingham Heart Study, decreased heart rate variability was associated with a substantially increased likelihood of major cardiac events (Figure 3).16 The Framingham investigators measured the standard deviation of R-R intervals that do not include ventricular ectopic beats (SDNN) as well as time-domain measures. Lower values of the ratio of low-frequency power to high-frequency power, which would correspond to lower levels of parasympathetic tone, were also associated with increased mortality. Similarly, among survivors of myocardial infarction, especially those with low ejection fractions, decreased heart rate variability predicted substantially higher mortality rates.5,17,18

 

 

Heart rate recovery

In 1999, Cole and colleagues reported on the association between heart rate recovery during the first minute after exercise and all-cause mortality in approximately 2,400 patients who were candidates for first-time coronary angiography.6 An abnormal heart rate recovery was defined as a reduction from the peak heart rate of 12 beats per minute or less, which corresponded to the lowest quartile. Thus, a patient achieving a peak heart rate of 160 beats per minute would be considered to have an abnormal heart rate recovery if 1 minute later the heart rate was 148 beats per minute or higher. Patients who had an abnormal heart rate recovery had a nearly fourfold increased risk of all-cause death; even after adjusting for numerous confounders, including exercise capacity, there was still a twofold independent increased risk of death. This initial observation has since been confirmed in other cohorts.19,20 The link between heart rate recovery, mortality, and cardiovascular prognosis appears to be independent of symptom status,21 type of recovery protocol,22 left ventricular ejection fraction,22 and angiographic severity of coronary artery disease.23

The mechanism by which an abnormal heart rate recovery predicts increased mortality is unclear. Given that heart rate recovery is thought to reflect parasympathetic nervous system function, and given that increased parasympathetic tone is believed to have antiarrhythmic effects, one might hypothesize that lower heart rate recovery would predict sudden cardiac death. In 2005, investigators from the Paris Civil Service Study reported on the association of exercise heart rate recovery and type of mortality; low heart rate recovery was strongly predictive of sudden cardiac death but not of non-sudden cardiac myocardial infarction death.20 A separate study from the Cleveland Clinic showed that among more than 29,000 patients, frequent ventricular ectopy during early recovery was strongly predictive of death, whereas frequent ventricular ectopy during exercise was not.24 These two studies together suggest that the link between heart rate recovery and mortality may be a reflection of the antiarrhythmic properties of the parasympathetic nervous system.

It is well known that there is an exceptionally powerful link between functional capacity and cardiovascular risk.25,26 People who are in excellent physical shape have high levels of parasympathetic tone. Among patients with suspected coronary artery disease, there is a strong dose-response relationship between heart rate recovery and physical fitness.6 While the link between functional capacity and prognosis is complex, it is conceivable that parasympathetic protection against arrhythmias and shear-induced plaque rupture may play a role.

Figure 4. User interface of an externally validated mortality prediction model for primary prevention patients with normal electrocardiograms undergoing exercise testing.27 This prediction model includes easily obtained cardiovascular risk factors as well as measures of autonomic function.
Both heart rate recovery and functional capacity are easy to measure using standard exercise test equipment. Recently, investigators from the Cleveland Clinic and Kaiser Permanente derived and externally validated a simple multivariable instrument by which all-cause mortality can be predicted in subjects with a normal electrocardiogram and no history of coronary disease.27 This instrument includes measures of functional capacity, heart rate recovery, and frequent ventricular ectopy during recovery. An example of the user interface is shown in Figure 4.

DETERMINANTS OF AUTONOMIC NERVOUS SYSTEM FUNCTION

There is an extensive literature documenting a number of determinants of autonomic tone.3,7 On a patient level, decreased levels of parasympathetic tone or increased levels of sympathetic tone have been linked to obesity, insulin resistance, diabetes, hypertension, hypercholesterolemia, depression, anxiety, heart failure, and peripheral vascular disease.3

Copyright © 2002 American Diabetes Association. From Diabetes®, Vol. 51, 2002; 803–807. Adapted with permission from The American Diabetes Association.
Figure 5. Association of fasting plasma glucose with abnormal heart rate recovery among healthy subjects enrolled in the Lipid Research Clinics observational cohort study.
The association between diabetes and autonomic nervous system dysfunction is well known to clinicians caring for patients with clinically manifest autonomic neuropathy. What is less appreciated is that even minor degrees of glucose intolerance are associated with abnormalities of autonomic balance. For example, among patients enrolled in a population-based cohort, the likelihood of an abnormal heart rate recovery increased in a steady fashion as fasting plasma glucose increased from 70 to 80 to 90 mg/dL and above (Figure 5).28 Even at levels of plasma glucose that would be considered normal, the likelihood of an abnormal heart rate recovery increased as plasma glucose increased.28

Perturbations of autonomic nervous system function have also been associated with environmental exposures. People who have lower levels of education,29 live in neighborhoods characterized by lower socio-economic status,30 or are exposed to small-particulate air pollution31 have been shown to manifest abnormal heart rate recovery or decreased heart rate variability.

CONCLUSIONS

Autonomic nervous system function can be measured in the clinic by recording resting heart rate, heart rate variability, or exercise heart rate recovery.1 All three of these measures are strong predictors of cardiovascular risk and all-cause mortality in both primary and secondary prevention settings. A number of determinants of autonomic nervous system function have been identified, including patient-level factors like obesity, diabetes, and heart failure as well as environmental correlates like smoking, social stress, and air pollution. It is not yet known, however, how best to take advantage of the associations between abnormal autonomic nervous system function and poor prognosis to improve patient outcomes. Future research will be needed to identify strategies of favorably modulating autonomic function that improve outcomes in the clinic and among large populations.

References
  1. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol 2008; 51:17251733.
  2. Katz A, Liberty IF, Porath A, Ovsyshcher I, Prystowsky EN. A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. Am Heart J 1999; 138(1 Pt 1):3238.
  3. Curtis BM, O’Keefe JH. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc 2002; 77:4554.
  4. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997; 30:11041106.
  5. Huikuri HV, Makikallio T, Airaksinen KE, Mitrani R, Castellanos A, Myerburg RJ. Measurement of heart rate variability: a clinical tool or a research toy? J Am Coll Cardiol 1999; 34:18781883.
  6. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999; 341:13511357.
  7. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 2007; 74:224242.
  8. van Ravenswaaij-Arts CM, Kollee LA, Hopman JC, Stoelinga GB, van Geijn HP. Heart rate variability. Ann Intern Med 1993; 118:436447.
  9. Pumprla J, Howorka K, Groves D, Chester M, Nolan J. Functional assessment of heart rate variability: physiological basis and practical applications. Int J Cardiol 2002; 84:114.
  10. Imai K, Sato H, Hori M, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol 1994; 24:15291535.
  11. Coburn AF, Grey RM, Rivera SM. Observations on the relation of heart rate, life span, weight and mineralization in the digoxintreated A-J mouse. Johns Hopkins Med J 1971; 128:169193.
  12. Custodis F, Baumhakel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008; 117:23772387.
  13. Wilhelmsen L, Berglund G, Elmfeldt D, et al. The multifactor primary prevention trial in GÖteborg, Sweden. Eur Heart J 1986; 7:279288.
  14. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 2007; 96:585592.
  15. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29:13271334.
  16. Tsuji H, Larson MG, Venditti FJ, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996; 94:28502855.
  17. Makikallio TH, Hoiber S, Kober L, et al. Fractal analysis of heart rate dynamics as a predictor of mortality in patients with depressed left ventricular function after acute myocardial infarction. TRACE Investigators. TRAndolapril Cardiac Evaluation. Am J Cardiol 1999; 83:836839.
  18. La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351:478484.
  19. Shetler K, Marcus R, Froelicher VF, et al. Heart rate recovery: validation and methodologic issues. J Am Coll Cardiol 2001; 38:19801987.
  20. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352:19511958.
  21. Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med 2000; 132:552555.
  22. Watanabe J, Thamilarasan M, Blackstone EH, Thomas JD, Lauer MS. Heart rate recovery immediately after treadmill exercise and left ventricular systolic dysfunction as predictors of mortality: the case of stress echocardiography. Circulation 2001; 104:19111916.
  23. Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am Coll Cardiol 2003; 42:831838.
  24. Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 2003; 348:781790.
  25. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793801.
  26. Gulati M, Black HR, Shaw LJ, et al. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med 2005; 353:468475.
  27. Lauer MS, Pothier CE, Magid DJ, Smith SS, Kattan MW. An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med 2007; 147:821828.
  28. Panzer C, Lauer MS, Brieke A, Blackstone E, Hoogwerf B. Association of fasting plasma glucose with heart rate recovery in healthy adults: a population-based study. Diabetes 2002; 51:803807.
  29. Shishehbor MH, Baker DW, Blackstone EH, Lauer MS. Association of educational status with heart rate recovery: a population-based propensity analysis. Am J Med 2002; 113:643649.
  30. Shishehbor MH, Litaker D, Pothier CE, Lauer MS. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA 2006; 295:784792.
  31. Magari SR, Hauser R, Schwartz J, Williams PL, Smith TJ, Christiani DC. Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation 2001; 104:986991.
References
  1. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol 2008; 51:17251733.
  2. Katz A, Liberty IF, Porath A, Ovsyshcher I, Prystowsky EN. A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. Am Heart J 1999; 138(1 Pt 1):3238.
  3. Curtis BM, O’Keefe JH. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc 2002; 77:4554.
  4. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997; 30:11041106.
  5. Huikuri HV, Makikallio T, Airaksinen KE, Mitrani R, Castellanos A, Myerburg RJ. Measurement of heart rate variability: a clinical tool or a research toy? J Am Coll Cardiol 1999; 34:18781883.
  6. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999; 341:13511357.
  7. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 2007; 74:224242.
  8. van Ravenswaaij-Arts CM, Kollee LA, Hopman JC, Stoelinga GB, van Geijn HP. Heart rate variability. Ann Intern Med 1993; 118:436447.
  9. Pumprla J, Howorka K, Groves D, Chester M, Nolan J. Functional assessment of heart rate variability: physiological basis and practical applications. Int J Cardiol 2002; 84:114.
  10. Imai K, Sato H, Hori M, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol 1994; 24:15291535.
  11. Coburn AF, Grey RM, Rivera SM. Observations on the relation of heart rate, life span, weight and mineralization in the digoxintreated A-J mouse. Johns Hopkins Med J 1971; 128:169193.
  12. Custodis F, Baumhakel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008; 117:23772387.
  13. Wilhelmsen L, Berglund G, Elmfeldt D, et al. The multifactor primary prevention trial in GÖteborg, Sweden. Eur Heart J 1986; 7:279288.
  14. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 2007; 96:585592.
  15. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29:13271334.
  16. Tsuji H, Larson MG, Venditti FJ, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996; 94:28502855.
  17. Makikallio TH, Hoiber S, Kober L, et al. Fractal analysis of heart rate dynamics as a predictor of mortality in patients with depressed left ventricular function after acute myocardial infarction. TRACE Investigators. TRAndolapril Cardiac Evaluation. Am J Cardiol 1999; 83:836839.
  18. La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351:478484.
  19. Shetler K, Marcus R, Froelicher VF, et al. Heart rate recovery: validation and methodologic issues. J Am Coll Cardiol 2001; 38:19801987.
  20. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352:19511958.
  21. Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med 2000; 132:552555.
  22. Watanabe J, Thamilarasan M, Blackstone EH, Thomas JD, Lauer MS. Heart rate recovery immediately after treadmill exercise and left ventricular systolic dysfunction as predictors of mortality: the case of stress echocardiography. Circulation 2001; 104:19111916.
  23. Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am Coll Cardiol 2003; 42:831838.
  24. Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 2003; 348:781790.
  25. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793801.
  26. Gulati M, Black HR, Shaw LJ, et al. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med 2005; 353:468475.
  27. Lauer MS, Pothier CE, Magid DJ, Smith SS, Kattan MW. An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med 2007; 147:821828.
  28. Panzer C, Lauer MS, Brieke A, Blackstone E, Hoogwerf B. Association of fasting plasma glucose with heart rate recovery in healthy adults: a population-based study. Diabetes 2002; 51:803807.
  29. Shishehbor MH, Baker DW, Blackstone EH, Lauer MS. Association of educational status with heart rate recovery: a population-based propensity analysis. Am J Med 2002; 113:643649.
  30. Shishehbor MH, Litaker D, Pothier CE, Lauer MS. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA 2006; 295:784792.
  31. Magari SR, Hauser R, Schwartz J, Williams PL, Smith TJ, Christiani DC. Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation 2001; 104:986991.
Page Number
S18-S22
Page Number
S18-S22
Publications
Publications
Article Type
Display Headline
Autonomic function and prognosis
Display Headline
Autonomic function and prognosis
Citation Override
Cleveland Clinic Journal of Medicine 2009 April;76(suppl 2):S18-S22
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Screening for coronary heart disease: Has the time for universal imaging arrived?

Article Type
Changed
Wed, 07/18/2018 - 15:45
Display Headline
Screening for coronary heart disease: Has the time for universal imaging arrived?
Article PDF
Author and Disclosure Information

Michael S. Lauer, MD
Director, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, National Institutes of Health; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 10122, Bethesda, MD 20892; e-mail: lauerm@nhlbi.nih.gov

Dr. Lauer receives support from the National Heart, Lung, and Blood Association (R01 HL-66004, R01 HL-072771, and P50 HL-77107, and K12 HD049091). He reports no personal financial relationships with any private commercial pharmaceutical, device, or imaging companies.

Issue
Cleveland Clinic Journal of Medicine - 74(9)
Publications
Topics
Page Number
645-650, 653-654, 656
Sections
Author and Disclosure Information

Michael S. Lauer, MD
Director, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, National Institutes of Health; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 10122, Bethesda, MD 20892; e-mail: lauerm@nhlbi.nih.gov

Dr. Lauer receives support from the National Heart, Lung, and Blood Association (R01 HL-66004, R01 HL-072771, and P50 HL-77107, and K12 HD049091). He reports no personal financial relationships with any private commercial pharmaceutical, device, or imaging companies.

Author and Disclosure Information

Michael S. Lauer, MD
Director, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, National Institutes of Health; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 10122, Bethesda, MD 20892; e-mail: lauerm@nhlbi.nih.gov

Dr. Lauer receives support from the National Heart, Lung, and Blood Association (R01 HL-66004, R01 HL-072771, and P50 HL-77107, and K12 HD049091). He reports no personal financial relationships with any private commercial pharmaceutical, device, or imaging companies.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 74(9)
Issue
Cleveland Clinic Journal of Medicine - 74(9)
Page Number
645-650, 653-654, 656
Page Number
645-650, 653-654, 656
Publications
Publications
Topics
Article Type
Display Headline
Screening for coronary heart disease: Has the time for universal imaging arrived?
Display Headline
Screening for coronary heart disease: Has the time for universal imaging arrived?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Cardiovascular medicine update 2007: Perioperative risk, carotid angioplasty, drug-eluting stents, stronger statins

Article Type
Changed
Wed, 07/18/2018 - 11:42
Display Headline
Cardiovascular medicine update 2007: Perioperative risk, carotid angioplasty, drug-eluting stents, stronger statins
Article PDF
Author and Disclosure Information

Michael S. Lauer, MD
Departments of Cardiovascular Medicine and Quantitative Health Sciences, Cleveland Clinic; Professor of Medicine, Epidemiology, and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Departments of Cardiovascular Medicine and Quantitative Health Sciences, JJ40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: lauerm@ccf.org

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Issue
Cleveland Clinic Journal of Medicine - 74(7)
Publications
Topics
Page Number
505-511
Sections
Author and Disclosure Information

Michael S. Lauer, MD
Departments of Cardiovascular Medicine and Quantitative Health Sciences, Cleveland Clinic; Professor of Medicine, Epidemiology, and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Departments of Cardiovascular Medicine and Quantitative Health Sciences, JJ40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: lauerm@ccf.org

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Author and Disclosure Information

Michael S. Lauer, MD
Departments of Cardiovascular Medicine and Quantitative Health Sciences, Cleveland Clinic; Professor of Medicine, Epidemiology, and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Departments of Cardiovascular Medicine and Quantitative Health Sciences, JJ40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: lauerm@ccf.org

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 74(7)
Issue
Cleveland Clinic Journal of Medicine - 74(7)
Page Number
505-511
Page Number
505-511
Publications
Publications
Topics
Article Type
Display Headline
Cardiovascular medicine update 2007: Perioperative risk, carotid angioplasty, drug-eluting stents, stronger statins
Display Headline
Cardiovascular medicine update 2007: Perioperative risk, carotid angioplasty, drug-eluting stents, stronger statins
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Choosing the right coronary test

Article Type
Changed
Mon, 06/18/2018 - 12:16
Display Headline
Choosing the right coronary test
Article PDF
Author and Disclosure Information

Michael S. Lauer, MD
Series Editor
Departments of Cardiovascular Medicine and Quantitative Health Sciences, Cleveland Clinic; Departments of Medicine, Epidemiology, and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Issue
Cleveland Clinic Journal of Medicine - 74(2)
Publications
Topics
Page Number
122
Sections
Author and Disclosure Information

Michael S. Lauer, MD
Series Editor
Departments of Cardiovascular Medicine and Quantitative Health Sciences, Cleveland Clinic; Departments of Medicine, Epidemiology, and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Author and Disclosure Information

Michael S. Lauer, MD
Series Editor
Departments of Cardiovascular Medicine and Quantitative Health Sciences, Cleveland Clinic; Departments of Medicine, Epidemiology, and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 74(2)
Issue
Cleveland Clinic Journal of Medicine - 74(2)
Page Number
122
Page Number
122
Publications
Publications
Topics
Article Type
Display Headline
Choosing the right coronary test
Display Headline
Choosing the right coronary test
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

What is the best test for a patient with classic angina?

Article Type
Changed
Mon, 06/18/2018 - 12:24
Display Headline
What is the best test for a patient with classic angina?
Article PDF
Author and Disclosure Information

Michael S. Lauer, MD
Director, Exercise Stress Laboratory, Departments of Cardiovascular Medicine and Quantitative Health Sciences, Cleveland Clinic; Professor of Medicine, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Departments of Cardiovascular Medicine and Quantitative Health Sciences, JJ40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: lauerm@ccf.org

The author has received funding under National Institutes of Health grants R01 HL-66004-2, R01 HL072771-01, P50 HL-77107-1, and K12 HD049091-01.

Issue
Cleveland Clinic Journal of Medicine - 74(2)
Publications
Topics
Page Number
123-126
Sections
Author and Disclosure Information

Michael S. Lauer, MD
Director, Exercise Stress Laboratory, Departments of Cardiovascular Medicine and Quantitative Health Sciences, Cleveland Clinic; Professor of Medicine, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Departments of Cardiovascular Medicine and Quantitative Health Sciences, JJ40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: lauerm@ccf.org

The author has received funding under National Institutes of Health grants R01 HL-66004-2, R01 HL072771-01, P50 HL-77107-1, and K12 HD049091-01.

Author and Disclosure Information

Michael S. Lauer, MD
Director, Exercise Stress Laboratory, Departments of Cardiovascular Medicine and Quantitative Health Sciences, Cleveland Clinic; Professor of Medicine, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Departments of Cardiovascular Medicine and Quantitative Health Sciences, JJ40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: lauerm@ccf.org

The author has received funding under National Institutes of Health grants R01 HL-66004-2, R01 HL072771-01, P50 HL-77107-1, and K12 HD049091-01.

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 74(2)
Issue
Cleveland Clinic Journal of Medicine - 74(2)
Page Number
123-126
Page Number
123-126
Publications
Publications
Topics
Article Type
Display Headline
What is the best test for a patient with classic angina?
Display Headline
What is the best test for a patient with classic angina?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Should we screen for abdominal aortic aneurysms?

Article Type
Changed
Mon, 07/23/2018 - 07:53
Display Headline
Should we screen for abdominal aortic aneurysms?
Article PDF
Author and Disclosure Information

Ahmed Abdel Latif, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Amjad AlMahameed, MD, MPH
Section of Vascular Medicine, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Michael S. Lauer, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Address: Amjad AlMahameed, MD, Section of Vascular Medicine, S60, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail almahaa@ccf.org

Issue
Cleveland Clinic Journal of Medicine - 73(1)
Publications
Topics
Page Number
9-10, 13, 16-17, 21-22
Sections
Author and Disclosure Information

Ahmed Abdel Latif, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Amjad AlMahameed, MD, MPH
Section of Vascular Medicine, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Michael S. Lauer, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Address: Amjad AlMahameed, MD, Section of Vascular Medicine, S60, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail almahaa@ccf.org

Author and Disclosure Information

Ahmed Abdel Latif, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Amjad AlMahameed, MD, MPH
Section of Vascular Medicine, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Michael S. Lauer, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Address: Amjad AlMahameed, MD, Section of Vascular Medicine, S60, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail almahaa@ccf.org

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 73(1)
Issue
Cleveland Clinic Journal of Medicine - 73(1)
Page Number
9-10, 13, 16-17, 21-22
Page Number
9-10, 13, 16-17, 21-22
Publications
Publications
Topics
Article Type
Display Headline
Should we screen for abdominal aortic aneurysms?
Display Headline
Should we screen for abdominal aortic aneurysms?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Coronary artery disease in diabetes: Which (if any) test is best?

Article Type
Changed
Tue, 05/03/2022 - 16:09
Display Headline
Coronary artery disease in diabetes: Which (if any) test is best?
Article PDF
Author and Disclosure Information

Michael S. Lauer, MD
Director, Exercise Stress Laboratory, Director of Clinical Research, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail Lauerm@ccf.org

Dr. Lauer is supported by grant HL-66004 from the National Heart, Lung, and Blood Institute of the National Institutes of Health.

Issue
Cleveland Clinic Journal of Medicine - 72(1)
Publications
Topics
Page Number
6, 8-9
Sections
Author and Disclosure Information

Michael S. Lauer, MD
Director, Exercise Stress Laboratory, Director of Clinical Research, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail Lauerm@ccf.org

Dr. Lauer is supported by grant HL-66004 from the National Heart, Lung, and Blood Institute of the National Institutes of Health.

Author and Disclosure Information

Michael S. Lauer, MD
Director, Exercise Stress Laboratory, Director of Clinical Research, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail Lauerm@ccf.org

Dr. Lauer is supported by grant HL-66004 from the National Heart, Lung, and Blood Institute of the National Institutes of Health.

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 72(1)
Issue
Cleveland Clinic Journal of Medicine - 72(1)
Page Number
6, 8-9
Page Number
6, 8-9
Publications
Publications
Topics
Article Type
Display Headline
Coronary artery disease in diabetes: Which (if any) test is best?
Display Headline
Coronary artery disease in diabetes: Which (if any) test is best?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Who should be taking aspirin to prevent coronary events?

Article Type
Changed
Fri, 11/16/2018 - 09:21
Display Headline
Who should be taking aspirin to prevent coronary events?
Article PDF
Author and Disclosure Information

Michael S. Lauer, MD
Director of Clinical Research, Department of Cardiovascular Medicine, The Cleveland Clinic; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: lauerm@ccf.org

Issue
Cleveland Clinic Journal of Medicine - 70(12)
Publications
Topics
Page Number
1076-1080
Sections
Author and Disclosure Information

Michael S. Lauer, MD
Director of Clinical Research, Department of Cardiovascular Medicine, The Cleveland Clinic; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: lauerm@ccf.org

Author and Disclosure Information

Michael S. Lauer, MD
Director of Clinical Research, Department of Cardiovascular Medicine, The Cleveland Clinic; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: lauerm@ccf.org

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 70(12)
Issue
Cleveland Clinic Journal of Medicine - 70(12)
Page Number
1076-1080
Page Number
1076-1080
Publications
Publications
Topics
Article Type
Display Headline
Who should be taking aspirin to prevent coronary events?
Display Headline
Who should be taking aspirin to prevent coronary events?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Using aspirin and ACE inhibitors in combination: Why the hullabaloo?

Article Type
Changed
Fri, 01/25/2019 - 08:30
Display Headline
Using aspirin and ACE inhibitors in combination: Why the hullabaloo?
Article PDF
Author and Disclosure Information

John G. Peterson, MD
Staff cardiologist, Spokane Cardiology, Spokane,WA

Michael S. Lauer, MD
Director of Clinical Research, Department of Cardiology, Cleveland Clinic

Address: Michael S. Lauer, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, lauerm@ccf.org

Issue
Cleveland Clinic Journal of Medicine - 68(6)
Publications
Topics
Page Number
569-574
Sections
Author and Disclosure Information

John G. Peterson, MD
Staff cardiologist, Spokane Cardiology, Spokane,WA

Michael S. Lauer, MD
Director of Clinical Research, Department of Cardiology, Cleveland Clinic

Address: Michael S. Lauer, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, lauerm@ccf.org

Author and Disclosure Information

John G. Peterson, MD
Staff cardiologist, Spokane Cardiology, Spokane,WA

Michael S. Lauer, MD
Director of Clinical Research, Department of Cardiology, Cleveland Clinic

Address: Michael S. Lauer, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, lauerm@ccf.org

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 68(6)
Issue
Cleveland Clinic Journal of Medicine - 68(6)
Page Number
569-574
Page Number
569-574
Publications
Publications
Topics
Article Type
Display Headline
Using aspirin and ACE inhibitors in combination: Why the hullabaloo?
Display Headline
Using aspirin and ACE inhibitors in combination: Why the hullabaloo?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Resuscitating the exercise stress test

Article Type
Changed
Mon, 03/11/2019 - 08:16
Display Headline
Resuscitating the exercise stress test
Article PDF
Author and Disclosure Information

Michael S. Lauer, MD
Co-director, Coronary Intensive Care Unit; Department of Cardiology, Cleveland Clinic

Issue
Cleveland Clinic Journal of Medicine - 66(5)
Publications
Page Number
278-282
Sections
Author and Disclosure Information

Michael S. Lauer, MD
Co-director, Coronary Intensive Care Unit; Department of Cardiology, Cleveland Clinic

Author and Disclosure Information

Michael S. Lauer, MD
Co-director, Coronary Intensive Care Unit; Department of Cardiology, Cleveland Clinic

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 66(5)
Issue
Cleveland Clinic Journal of Medicine - 66(5)
Page Number
278-282
Page Number
278-282
Publications
Publications
Article Type
Display Headline
Resuscitating the exercise stress test
Display Headline
Resuscitating the exercise stress test
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Article PDF Media